​

Kiniksa Pharmaceuticals (KNSA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Kiniksa Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$423.24M

Latest Revenue (Q)

$137.78M

Main Segment (Y)

Product

Kiniksa Pharmaceuticals Revenue by Period

Kiniksa Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$423.24M56.60%
2023-12-31$270.26M22.74%
2022-12-31$220.18M471.24%
2021-12-31$38.54M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31--

Kiniksa Pharmaceuticals generated $423.24M in revenue during NA 2024, up 56.60% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Kiniksa Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-03-31$137.78M12.44%
2024-12-31$122.54M9.20%
2024-09-30$112.21M3.30%
2024-06-30$108.63M36.03%
2024-03-31$79.86M-4.24%
2023-12-31$83.39M24.38%
2023-09-30$67.05M-6.19%
2023-06-30$71.47M47.84%
2023-03-31$48.34M-21.88%
2022-12-31$61.88M-37.58%
2022-09-30$99.14M267.55%
2022-06-30$26.97M-16.21%
2022-03-31$32.19M71.72%
2021-12-31$18.75M54.98%
2021-09-30$12.10M57.00%
2021-06-30$7.70M100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31--

Kiniksa Pharmaceuticals generated $137.78M in revenue during Q1 2025, up 12.44% compared to the previous quarter, and up 165.22% compared to the same period a year ago.

Kiniksa Pharmaceuticals Revenue Breakdown

Kiniksa Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22
Product$417.03M$233.18M$122.52M
Collaboration$6.21M$37.08M$97.66M

Kiniksa Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (98.53%), and Collaboration (1.47%).

Quarterly Revenue by Product

Product/ServiceMar 25Dec 24Sep 24Jun 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22
Product$137.78M$201.42M$112.21M$103.39M$136.02M$54.49M$42.66M$39.94M$33.42M$26.97M$22.19M
Collaboration--$6.21M$5.24M$14.42M$16.98M$5.69M$21.95M---

Kiniksa Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Product (100.00%).

Kiniksa Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
KNSAKiniksa Pharmaceuticals$423.24M$137.78M
MIRMMirum Pharmaceuticals$336.89M$99.41M
IMCRImmunocore$310.20M$84.05M
YMABY-mAbs Therapeutics$87.69M$20.90M
LYRALyra Therapeutics$1.53M$209.00K
CRNXCrinetics Pharmaceuticals$1.04M-
RCKTRocket Pharmaceuticals--
KALVKalVista Pharmaceuticals--
REPLReplimune Group--
SRRKScholar Rock--
LRMRLarimar Therapeutics--

KNSA Revenue FAQ

What is Kiniksa Pharmaceuticals’s yearly revenue?

Kiniksa Pharmaceuticals's yearly revenue for 2024 was $423.24M, representing an increase of 56.60% compared to 2023. The company's yearly revenue for 2023 was $270.26M, representing an increase of 22.74% compared to 2022. KNSA's yearly revenue for 2022 was $220.18M, representing an increase of 471.24% compared to 2021.

What is Kiniksa Pharmaceuticals’s quarterly revenue?

Kiniksa Pharmaceuticals's quarterly revenue for Q1 2025 was $137.78M, a 12.44% increase from the previous quarter (Q4 2024), and a 72.54% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $122.54M, a 9.20% increase from the previous quarter (Q3 2024), and a 46.93% increase year-over-year (Q4 2023). KNSA's quarterly revenue for Q3 2024 was $112.21M, a 3.30% increase from the previous quarter (Q2 2024), and a 67.37% increase year-over-year (Q3 2023).

What is Kiniksa Pharmaceuticals’s revenue growth rate?

Kiniksa Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 92.22%, and for the last 5 years (2020-2024) was 0%.

What are Kiniksa Pharmaceuticals’s revenue streams?

Kiniksa Pharmaceuticals's revenue streams in c 24 are Product, and Collaboration. Product generated $417.03M in revenue, accounting 98.53% of the company's total revenue, up 78.85% year-over-year. Collaboration generated $6.21M in revenue, accounting 1.47% of the company's total revenue, down -83.25% year-over-year.

What is Kiniksa Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Kiniksa Pharmaceuticals was Product. This segment made a revenue of $417.03M, representing 98.53% of the company's total revenue.